Gout Pipeline Looks Past Uloric To Resistant Patients, Acute Flares

Takeda’s Uloric (febuxostat) ended a forty-year drought for new gout treatments when FDA approved the oral drug for chronic disease on Feb. 13, but a pipeline stocked with new drugs holds the promise of a shorter wait for the next gout therapy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet